In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cerexa Inc.

Division of Allergan PLC
www.cerexa.com

Latest From Cerexa Inc.

Agenovir: Using Gene Editing To Kill Viral DNA

Emerging Company Profile: Agenovir has a unique gene-editing niche – using CRISPR/Cas9 to destroy DNA in latent viral reservoirs as opposed to other companies that snip and repair errors in the genome.

StartUps and SMEs Business Strategies

Flexibility Or Formal Pathway? Avycaz Suggests FDA Doesn't Need Congress To Expedite Limited Use Antibiotics

FDA steered Actavis' antibiotic Avycaz to approval for limited use based on limited data through the 505(b)(2) pathway, helped along by the agency's regulatory flexibility for medically important agents – making the Limited Population Antibiotic Development pathway under discussion on Capitol Hill look redundant.

BioPharmaceutical Regulation

Drug Development Wish List: Antibiotic Data Cravings Seen At Actavis Cmte. Review

Despite voting for two of three proposed indications for gram-negative antibiotic ceftazidime/avibactam, many FDA committee members pressed for additional studies and analyses, offering hints for future antibiotic advisory panels as well as potential post-market requirements for Actavis.

BioPharmaceutical North America

Reinvigorated Antibiotics Pipeline Could Produce Four NMEs In 2014

With two novel antibiotics approved and two more under review, 2014 is seeing the end of a long lean period for antibacterial R&D, helped by incentives like Qualified Infectious Disease Product designation. But only one candidate, Cubist’s ceftozolane/tazobactam, addresses the urgent need to target resistant Gram-negative bacteria.

BioPharmaceutical Regulation
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Allergan PLC
  • Senior Management
  • Dennis G Podlesak, Pres. & CEO
    Stan E Abel, CFO
    James Ge, MD, VP, Drug Dev.
  • Contact Info
  • Cerexa Inc.
    Phone: (510) 747-3900
    1751 Harbor Bay Pkwy.
    Alameda, CA 94502
    USA
UsernamePublicRestriction

Register